Acquisitions3 Apr 2025, 12:42 am
Lupin Ltd Acquires Renascience Pharma Limited for GBP 12.3 Million
AI Summary
Lupin Ltd, a global pharmaceutical leader, announced the acquisition of Renascience Pharma Limited, a UK-based pharmaceutical company. Lupin Healthcare (UK) Limited, a wholly owned subsidiary of Lupin Ltd, acquired the entire share capital of Renascience Pharma Limited for a cash consideration of GBP 12.3 million. Renascience Pharma Limited is a licensee and sole supplier of four niche Bio-Generics products to the primary and secondary care market in the UK, with no local generics competition. The acquisition aims to extend Lupin's portfolio offering of specialty pharmaceuticals in the United Kingdom.
Key Highlights
- Lupin Ltd acquires Renascience Pharma Limited for GBP 12.3 million in cash.
- Renascience Pharma Limited is a licensee and sole supplier of four niche Bio-Generics products in the UK with no local generics competition.
- The acquisition aims to extend Lupin's portfolio offering of specialty pharmaceuticals in the United Kingdom.
- Renascience Pharma Limited has a brand portfolio that consists of two Injectables for (non-viral) infectious diseases, ear drops for pain management, and oral therapy for indications in cardiology and nephrology.
- The acquisition has been completed simultaneously with the execution of the definitive agreement today i.e. April 02, 2025.